Due to the desire to both shorten the length and reduce the size of clinical trials in human immunodeficiency virus (HIV) disease, the use of surrogate end points such as HIV-1 RNA is becoming increasingly standard. While these end points may be reasonable surrogates for the clinical effectiveness of drugs, a key point in their use as trial end points is the definition of a relevant duration of antiviral response. This definition is often complicated by the desire to perform interim reviews of ongoing laboratory end point trials. Unlike clinical end point trials, in which early clinical response is generally indicative of longer-term follow-up, it is yet to be determined whether shortterm viral response adequately predicts the long-term durability of that response.
There has been increasing movement in the human immunofollow-up week, typically weeks 24 or 48. However, with the advent of more potent antiretroviral therapies, particularly prodeficiency virus (HIV) clinical trials community toward greater use of laboratory measures of biologic activity in the conduct tease inhibitor -containing regimens, recent interest has focused on end points defined in terms of the lower limit of and analysis of clinical trials of antiretroviral therapies [1, 2] . The use of laboratory markers in HIV clinical trials was historiquantification of the HIV-1 RNA assay, based on current theories about disease pathogenesis and viral resistance [14] . For cally motivated by a desire to shorten the duration and reduce the required number of patients of such clinical trials [3, 4] clinical trials involving patients with initially detectable HIV-1 RNA levels, such end points are typically defined in terms and more recently due to a better understanding of HIV dynamics [5 -7] . The use of these laboratory markers implies that of the proportion with undetectable levels at a given followchanges in specific measures of in vivo virologic or immunoup week (e.g., AIDS Clinical Trials Group [ACTG] 347). For logic responses to antiretroviral therapies are associated with clinical trials involving patients with initially undetectable clinical benefit [8 -10] . HIV-1 RNA copy number is such a HIV-1 RNA levels, the end point is typically defined as the laboratory marker [11, 12] , and frequent HIV-1 RNA monitorproportion of patients who experience reemergence of detecting is rapidly becoming the standard of care in routine clinical able HIV-1 RNA by a given follow-up week (e.g., ACTG 343). practice; many clinical trials currently use HIV-1 RNA copy Each of these choices of end points has unique problems when number as their primary end point. Interim monitoring or early used for interim monitoring of HIV-1 RNA measurements. evaluation of HIV clinical trials on the basis of laboratory We need to consider how interim monitoring should reflect markers is now considered ethically necessary by both patients the specific questions being asked by the study. The question and physicians and is thus essential if such clinical trials are of primary interest may be whether there exists a treatment to be conducted. difference with regard to initial drop in HIV-1 RNA level or Change in HIV-1 RNA levels can be documented in a variety with regard to the duration of suppression of HIV-1 RNA of ways when assessing the activity of antiretroviral therapies (durability). We also need to assess the potential reasons for [13] . The usefulness of interim monitoring of HIV-1 RNA early stopping of a clinical trial on the basis of interim monitorlevels in antiretroviral clinical trials will depend critically on ing. One reason to stop a study, or an arm of a study, is the the manner in which the HIV-1 RNA end point is defined. failure of one or more treatments to affirm expectations (i.e., Until recently, HIV-1 RNA end points have been defined in a prespecified minimum acceptable drop in HIV-1 RNA is terms of the change from baseline level to a predetermined not achieved). Another reason to stop a study is the obvious superiority of one treatment at a planned primary analysis time point or implied superiority based on results at an earlier time point. There are well-established statistical adjustments for levels across three ACTG studies (175, 229, and 241) showed very high correlation between HIV-1 RNA responses at weeks 8 and 24 and those at week 48 (figure 1; [15] ). This suggests be evaluated cautiously with regard to their applicability to current clinical trials of more potent agents. that intermediate follow-up times may provide useful information when the primary end point is change in HIV-1 RNA For potent therapies with which the appropriate end point is the proportion reaching and maintaining undetectable HIV-1 level. Appropriate statistical methods must be developed for hypothesis testing based on interim monitoring under this situa-RNA levels, the extent to which HIV-1 RNA levels at intermediate follow-up times are indicative of those at later follow-up tion.
It should be emphasized that a high correlation of weeks 8, times is currently under investigation. In particular, the key point of interest in such clinical trials is the length of time for 24, and 48 marker response data is a necessary but not sufficient condition for the use of week 8 and 24 marker data to imply which HIV-1 RNA levels can be suppressed. Data from early follow-up times may not be informative about the duration of week 48 marker outcomes. 1 RNA response, as patients are followed (for the analysis) the end of the study than does the O'Brien-Fleming rule to achieve the desired level of significance. The O'Brien-Fleming only until the time that their level of HIV-1 RNA becomes undetectable. It is their time to viral reemergence that provides rule tends to continue studies to their planned termination. When early follow-up HIV-1 RNA levels are used to impute insight into treatment durability.
For any clinical trial that includes preplanned sequential monilevels at a later follow-up time, additional problems must be considered. There is a need not only to preserve the desired toring of treatment effects, the choice of stopping rules is of special importance. This choice must be made in advance, with overall significance level through methods of sequential monitoring, but also to be confident that there is sufficient evidence to a balance of underlying assumptions and safeguards. Two commonly used stopping criteria are those of Pocock [16] and ensure that the imputation is valid. In this setting, early stopping has an additional drawback; not only is less information gathered O'Brien and Fleming [17] . These choices ensure that repeated tests of treatment effects will be valid at a prespecified level of about the durability of treatment effects, but also fewer data will be available to validate the imputation. Statistical theory that significance. In the case of the Pocock stopping rule, the P value required to reject the null hypothesis remains constant over all accounts for the imputed nature of the data is currently being developed for hypothesis testing of the primary end point. interim analysis times, whereas the O'Brien-Fleming rule requires much more substantiated treatment effects at early interim Table 1 provides examples under which imputation may be more or less valid. In the first example, patients show durability analyses, but a significance level at the final analysis that is close to the overall P value (generally .05). The Pocock rule in their HIV-1 RNA detectability; the detectability observed at week 24 always properly implies the detectability at week 48. allows stopping at an earlier analysis time with less extreme treatment differences but requires larger treatment differences at Under these circumstances, while the criteria for significance must be adjusted for multiple comparisons (multiple interim data on the impact of specific treatment regimens on the success of specific subsequent regimens. Only by considering this inforanalyses), no further penalty for premature decision need be imposed. In the second example, however, week 24 does not mation and data on the toxicity profiles of different regimens can a well-informed long-term treatment strategy be developed. always predict week 48. In this situation, an extra penalty should be imposed due to the uncertain relationship between
In summary, we believe that developing appropriate statistical methods for early termination of HIV clinical trials based the early and later outcomes. Only if there is sufficient reason to assume that the first scenario is true is the Pocock rule on preliminary HIV-1 RNA findings is of critical importance. It is essential that interim analyses reflect the primary end reasonable. Under the second scenario, the more stringent criteria for early stopping provided by the O'Brien-Fleming rule is point and that early study termination must be based on the evaluation, either directly or by implication, of the primary end likely to be preferred. Continuation of the clinical trial may also provide the information necessary to further understand point. This is particularly important for HIV clinical trials in which durability of therapeutic response is the primary study the relationship between early and late HIV-1 RNA levels. This decision must be weighed carefully, taking into account question, since great care must be taken to distinguish acute treatment-induced effects from their durability. a variety of complicating issues.
One such issue is due to the likelihood that response to new We believe that in some carefully defined circumstances, interim HIV-1 RNA data in conjunction with available comtreatments is dependent not only on the duration of previous treatment, but also the specific nature of previous treatments.
plete follow-up data could form the basis for early termination of a clinical trial. If there are already conclusive data from It is reasonable to assume that certain treatment regimens may induce viral resistance (either complete or partial) to subsequent other clinical trials about the relationship between HIV-1 RNA response at earlier time points and at the primary end point, regimens [18] . For this reason, it is our view that interim values of HIV-1 RNA do not capture all of the information needed then basing interim analyses on earlier time points may be justified as long as the additional uncertainty inherent in proto plan long-term treatment strategies. We also need to gather jecting later responses from early data is taken properly into account. If the information about this relationship is unavailable from an external source, then accumulating data from patients 
